Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

MLA

Chen-Yang Shen, et al. “Assessment of Variation in Immunosuppressive Pathway Genes Reveals TGFBR2 to Be Associated with Prognosis of Estrogen Receptor-Negative Breast Cancer after Chemotherapy.” Breast Cancer Research, vol. 17, no. 1. EBSCOhost, https://doi.org/10.1186/s13058-015-0522-2. Accessed 11 Nov. 2024.

APA

Chen-Yang Shen, Keun-Young Yoo, Kazuo Tajima, Georgia Chenevix-Trench, Qin Wang, William J. Tapper, Kristiina Aittomäki, Douglas F. Easton, Anne Lise Børresen-Dale, Ann Smeets, Hidemi Ito, Heli Nevanlinna, Kamila Czene, Sabine C. Linn, Soo Hwang Teo, Tom Maishman, Ursula Eilber, Robert Luben, Jolanta Lissowska, … Agnes Jager. (n.d.). Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Research, 17(1). https://doi.org/10.1186/s13058-015-0522-2

Chicago

Chen-Yang Shen, Keun-Young Yoo, Kazuo Tajima, Georgia Chenevix-Trench, Qin Wang, William J. Tapper, Kristiina Aittomäki, et al. 2024. “Assessment of Variation in Immunosuppressive Pathway Genes Reveals TGFBR2 to Be Associated with Prognosis of Estrogen Receptor-Negative Breast Cancer after Chemotherapy.” Breast Cancer Research 17 (1). Accessed November 11. doi:10.1186/s13058-015-0522-2.